AstraZeneca has announced the suspension of a 200 million pound investment in the research center in Cambridge, affecting 1,000 jobs.

AstraZeneca has decided to halt its £200 million investment plan at its research center in Cambridge, a project that would have created approximately 1,000 jobs. This is the company's second major withdrawal from the UK in 2024, after it abandoned a £450 million investment in vaccine manufacturing in January. The decisions of pharmaceutical companies, including Merck & Co., are putting pressure on the British government in the context of maintaining attractiveness for investments in the pharmaceutical sector.